During the last World Ophthalmology Congress held in Barcelona, Spain, June 17-19, Quantel Medical launched LacryDiag, a complete diagnostic device for dry eye. LacryDiag is the first step of Quantel Medical in the dry eye market.
Dry eye is a particularly common disease that affects the health and well-being of more than 300 millions of people worldwide. LacryDiag is an ocular surface analyzer that complies with the dry eye diagnosis recommendations established in the DEWS II report. This device is CE marked and is approved by the U.S. Food and Drug Administration (FDA).
It offers a fast and complete analysis of the three tear film layers with 4 non-contact exams:
- Interferometry: diagnosis of the lipid layer
- N.I.B.U.T.: diagnosis of the mucin layer
- Tear meniscus: diagnosis of the aqueous layer
- Meibography: diagnosis of the meibomian glands.
“Dry eye is a real public health problem but the symptoms are often misunderstood. As a multifactorial pathology that results from damage to the tear film due, this pathology is often underdiagnosed and underestimated, explains Jean-Marc Gendre, CEO Quantel Medical. With LacryDiag, the ophthalmologists are now able to diagnosis in few minutes the three tear film layers to select a personalized treatment for the patient.”
Impacting all ages and occurring after surgical procedures such as Lasik or cataract surgery, Dry Eye is now recognized as a disease and the number of publications about this subject has almost doubled in 10 years.